Evolus Inc

NASDAQ:EOLSUnited States

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Contact Information

Headquarters

520 Newport Center Dr Ste 1200NEWPORT BEACH, CA, United States 92660-7022

Phone

949-284-4555

Fax

302-636-5454

Executives

Independent Chairman of the Board

Vikram Malik

President, Chief Executive Officer, Director

David Moatazedi

Chief Financial Officer

Sandra Beaver

Chief Marketing Officer

Tomoko Yamagishi-Dressler

Chief Medical Officer, Head - Research and Development

Rui Avelar